PODCAST: Announcing Crowell & Moring’s Regulatory Forecast 2017 and Trump: The First Year Series — C&M's Trump: The First Year Series
Client Alert | 1 min read | 05.11.17
On May 9, Crowell & Moring launched its third annual Regulatory Forecast. The 2017 edition, subtitled “What Trump Means for Business,” provides in-depth analysis on how the new administration, Congress, and the federal courts are changing the regulatory landscape and what it means for business in the months ahead. With this publication, we are also announcing the launch of our new Trump: The First Year series about the regulatory changes emerging from the White House under the new administration. In this first episode of the series, Regulatory Forecast co-editors Dan Wolff and Richard Lehfeldt sit down to discuss the Forecast and what to expect from the series.
In this 12 minute podcast, Richard and Dan discuss what you will find in our Regulatory Forecast 2017 and what lessons businesses should take from the publication. The forecast is available at crowell.com/regulatoryforecast.
Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes
Contacts
Insights
Client Alert | 8 min read | 06.30.25
AI Companies Prevail in Path-Breaking Decisions on Fair Use
Last week, artificial intelligence companies won two significant copyright infringement lawsuits brought by copyright holders, marking an important milestone in the development of the law around AI. These decisions – Bartz v. Anthropic and Kadrey v. Meta (decided on June 23 and 25, 2025, respectively), along with a February 2025 decision in Thomson Reuters v. ROSS Intelligence – suggest that AI companies have plausible defenses to the intellectual property claims that have dogged them since generative AI technologies became widely available several years ago. Whether AI companies can, in all cases, successfully assert that their use of copyrighted content is “fair” will depend on their circumstances and further development of the law by the courts and Congress.
Client Alert | 3 min read | 06.30.25
Client Alert | 3 min read | 06.26.25
FDA Targets Gene Editing Clinical Trials in China and other “Hostile Countries”
Client Alert | 3 min read | 06.26.25
